Literature DB >> 19667278

Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.

Catharina M Korse1, Babs G Taal, Cornelis A de Groot, Robert H Bakker, Johannes M G Bonfrer.   

Abstract

PURPOSE: For the last decade chromogranin-A (CgA) has been a well-established marker for neuroendocrine tumor (NET), and N-terminal pro-brain natriuretic peptide (NT-proBNP) has been a useful marker for left ventricular dysfunction. This study examined the diagnostic value of CgA and NT-proBNP for carcinoid heart disease (CHD), and their prognostic value for overall survival in NET patients. PATIENTS AND METHODS: Serum samples were obtained and cardiac ultrasound studies performed in 102 NET patients. The criterion for mild and severe CHD was tricuspid regurgitation stage I/II and III/IV, respectively. Proportional odds and Cox proportional hazards models were constructed respectively to identify the association between CHD and overall survival with patient characteristics and the two markers.
RESULTS: Severe CHD was found in 15 (15%) of 102 patients, 13 of whom had elevated NT-proBNP levels. In the univariate proportional odds model CHD was correlated with age (P = .007), CgA (P = .002), and NT-proBNP (P < .001), whereas in the multivariate model NT-proBNP and CgA were significantly associated with CHD (P < .001 and P = .01). In the univariate Cox models, age (P = .04), sex (P = .03), CgA (P = .003), and NT-proBNP (P = .04) were related to overall survival, and in the multivariate model CgA and NT-proBNP remained significantly related to overall survival (P = .002 and P = .04, respectively).
CONCLUSION: NT-proBNP and CgA are very important markers in the diagnosis of CHD in patients with NET. Furthermore, patients with elevated NT-proBNP in addition to elevated CgA levels showed worse overall survival than patients with elevated CgA alone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19667278     DOI: 10.1200/JCO.2008.18.7047

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  28 in total

Review 1.  Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework.

Authors:  Andrew J Vickers; Angel M Cronin
Journal:  Semin Oncol       Date:  2010-02       Impact factor: 4.929

2.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors.

Authors:  Gregory Kaltsas; Martyn Caplin; Philippa Davies; Diego Ferone; Rocio Garcia-Carbonero; Simona Grozinsky-Glasberg; Dieter Hörsch; Eva Tiensuu Janson; Reza Kianmanesh; Beata Kos-Kudla; Marianne Pavel; Anja Rinke; Massimo Falconi; Wouter W de Herder
Journal:  Neuroendocrinology       Date:  2017-03-02       Impact factor: 4.914

Review 3.  Carcinoid Heart Disease: Review of Current Knowledge.

Authors:  Pradhum Ram; Jorge L Penalver; Kevin Bryan U Lo; Janani Rangaswami; Gregg S Pressman
Journal:  Tex Heart Inst J       Date:  2019-02-01

Review 4.  Ileal neuroendocrine tumors and heart: not only valvular consequences.

Authors:  Jan Calissendorff; Eva Maret; Anders Sundin; Henrik Falhammar
Journal:  Endocrine       Date:  2014-10-16       Impact factor: 3.633

Review 5.  Carcinoid-syndrome: recent advances, current status and controversies.

Authors:  Tetsuhide Ito; Lingaku Lee; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2018-02       Impact factor: 3.243

Review 6.  Consensus on biomarkers for neuroendocrine tumour disease.

Authors:  Kjell Oberg; Irvin M Modlin; Wouter De Herder; Marianne Pavel; David Klimstra; Andrea Frilling; David C Metz; Anthony Heaney; Dik Kwekkeboom; Jonathan Strosberg; Timothy Meyer; Steven F Moss; Kay Washington; Edward Wolin; Eric Liu; James Goldenring
Journal:  Lancet Oncol       Date:  2015-09       Impact factor: 41.316

7.  Carcinoid valve disease.

Authors:  J Wells Askew; Heidi M Connolly
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-10

8.  Esomeprazole-induced hyperchromograninemia in the absence of concomitant hypergastrinemia.

Authors:  Giovanni Gori; Giacomo Spinelli; Claudio Spinelli; Marco Tuccori; Corrado Blandizzi; Mario Del Tacca
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-12       Impact factor: 46.802

9.  Association detection between ordinal trait and rare variants based on adaptive combination of P values.

Authors:  Meida Wang; Weijun Ma; Ying Zhou
Journal:  J Hum Genet       Date:  2017-11-07       Impact factor: 3.172

10.  Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.

Authors:  Monica Ter-Minassian; Jennifer A Chan; Susanne M Hooshmand; Lauren K Brais; Anastassia Daskalova; Rachel Heafield; Laurie Buchanan; Zhi Rong Qian; Charles S Fuchs; Xihong Lin; David C Christiani; Matthew H Kulke
Journal:  Endocr Relat Cancer       Date:  2013-03-22       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.